Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. - Wikidata - awgldk - TriplyDB

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

http://www.wikidata.org/entity/Q36512029

about

Does tuberculosis threaten our ageing populations?Clinical peculiarities of tuberculosis Undernutrition & tuberculosis in India: Situation analysis & the way forward Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1 Profile and response to anti-tuberculosis treatment among elderly tuberculosis patients treated under the TB Control programme in South India Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity Autoimmune-like drug-induced liver injury: a review and update for the clinician.Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).Antitubercular therapy in patients with cirrhosis: challenges and options Drug-induced liver injury in older adults.Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.Risk factors for idiosyncratic drug-induced liver injury.Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients.Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil.Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.Pharmacogenomics of anti-TB drugs-related hepatotoxicity.Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.Drug-induced autoimmune-like hepatitis.Drug-induced liver injury: the role of drug metabolism and transport.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Predictors of hepatotoxicity among patients treated with antituberculous medication.A comparison between two strategies for monitoring hepatic function during antituberculous therapy.Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis.Two cases of tuberculous peritonitis with liver cirrhosis complicated by refractory ascites.Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.

P2860

Q26766255-5D0B3A0F-C1EB-4AE3-9C59-D688AD4E7D44 Q27009986-B9FD5A60-3865-4971-A84E-8F2C5EC1E856 Q28078944-B111EC0C-6523-4839-B5C4-88738EADCEA5 Q28488142-1E4F0F59-D7B4-486C-BB49-3A1A46A21A53 Q28539060-6BD8D397-3202-42AB-8D4D-BEFFFC87719E Q28540716-4853A6DB-E9F2-4D02-BA6B-5864F6AB6DC9 Q28548334-8EB65A95-80B0-4822-8B1F-31005F82DAE0 Q28744372-C7F93AA5-1DB1-49E6-9D83-38E7775A45B7 Q30276377-A44477BE-DA44-4EAB-9E59-4A70E01C516D Q33584259-24F0179E-D0B0-4A37-982E-638DAC87EBCD Q33626827-705CE523-BD5E-448F-BDC4-975EF8D47FFD Q33949227-8B808447-2274-462D-811D-B6B5C3918C62 Q34116293-F675772C-38D7-41B2-BE22-330E9F13A966 Q34606196-5ECFA2D5-4AC1-4AAE-86F4-9279DBB04124 Q35168108-32F93C8B-6849-45E3-9386-54FC51F65182 Q35534713-EA3BB6D4-0C0A-4FB6-A947-914AE1E3C9A4 Q35911420-ED330283-C65A-4CC5-88DA-9747F518DB13 Q36190248-8C8C8CBB-85CB-4BAD-A863-43177145A490 Q36225416-EEA5406E-1981-4B49-A3E8-B36BE3BEB857 Q36725202-83BADFB6-B4AB-44E2-89E5-6660750913AD Q36727239-7CF0267E-863C-49D4-A8F2-8D5171F7F2E7 Q36740188-2305FF2D-0B2A-42C8-8286-1B1AF2FDBAD7 Q37043444-9D0B4E0C-4F20-4CC3-B77A-B79DC2381FF3 Q37096055-C98C8933-713E-4501-9BCF-D618794D3DFB Q37114268-5A318F93-F157-4A07-8B9B-A98DE9547211 Q37278221-F33A6407-8D66-489B-9FC4-E863AD1679D0 Q37613267-314A9C9F-8898-4849-B941-F20B7AD450AD Q37666631-7085B65C-4617-411D-932A-2F030226A401 Q37843783-63F15E37-7CBB-40AB-9208-0A5F5C4A4B49 Q38084215-8A6FA257-43CE-4EBE-9FDC-24768C0C7D59 Q38360770-38BD91C9-E304-412B-96ED-85B4B3D313CE Q38964386-65544EA8-59AB-4E73-B48D-ADF10A4717B1 Q40013706-21F1B0D6-7290-4810-AF43-E031F0D8EF2E Q40035394-99942593-7F40-4174-B316-464507572897 Q40322550-26B10CE5-479E-4A1C-A820-D7D426F540A1 Q40383537-2B1AC742-E894-4494-A20F-010D91C47919 Q40723805-BA9F77F7-6FB9-4103-958E-20E89D1FAABD Q41684440-1DA16608-F364-4828-A465-8C1628548A25 Q42251941-17E67659-652E-4253-B4F5-7E26C157AEBC Q42278836-419760FA-9EBE-43BF-B6E0-88681735DEF3

P2860

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

http://www.wikidata.org/entity/Q36512029

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@ast

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@en

type

label

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@ast

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@en

prefLabel

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@ast

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@en

P1433

Q36512029-02B24ADD-0A46-404D-9C84-86E25D0B0B35

P1476

Q36512029-51DBFAE8-AB2B-461B-8682-BDED67C96C68

P2093

Q36512029-1895155B-66B5-449E-8286-8AE65EA91FDE

Q36512029-4EE49D6C-1759-4DAC-B8A8-8A56074FDF5C

Q36512029-C5714B19-3693-4F69-B402-7406F66D24DA

Q36512029-CCBD4FD4-7E02-4FA0-9323-3E5963C92049

Q36512029-E777BD57-A1BD-4220-A857-B033EA5FFC9C

P2860

Q36512029-25E612E5-A4D8-4A4B-9267-62EA2FDC1F2F

Q36512029-27F439C9-EAF8-426E-8A32-C27D806734B2

Q36512029-2C2009D5-392A-4860-AF58-E6A71401B801

Q36512029-47DD55BB-F490-4101-9CFD-51FC874CBB93

Q36512029-4DAC0D05-C5A2-4869-9FB6-1AC510C8A609

Q36512029-7145A583-9023-4C9E-BE39-81A3D20E71DE

Q36512029-9E4F9C8E-02E4-4D25-BFCE-8F38DF2F0420

Q36512029-AA14607C-F2EC-4013-AD35-51DC9B991C9F

Q36512029-AB4ADD7E-B774-4C9C-A11E-D2832EB4D1DB

Q36512029-BBCD239B-FC6F-40C4-A7CB-D689628D7D56

P304

Q36512029-87D4B26A-664C-49D2-AEE5-2A1CAC236056

P31

Q36512029-64EE17E9-594D-40D4-A1F7-635B8C6CEF31

P356

Q36512029-FE545CD3-7666-4900-9E25-0335E387EC0F

P407

Q36512029-39D89188-5189-49DF-BEA8-332CC335D60C

P433

Q36512029-CECFE129-829D-479F-AE9D-32905082AB11

P478

Q36512029-281DB738-AEE7-4392-8042-A6A5A7B07031

P577

Q36512029-801E8EE6-58E7-45B1-A5FB-1E2F8479E52E

P5875

Q36512029-828B2E99-C607-49EC-A2F1-19C0BB916D77

P698

Q36512029-473495C6-6A65-499C-89D7-386918CACBED

P921

Q36512029-59FB80A4-D967-42E9-9A60-726D990D62E4

P932

Q36512029-DDBAA177-8F27-4210-8524-1732F7E5AE20

P356

P1433

P1476

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

@en

P2093

G C Khilnani

http://www.w3.org/2001/XMLSchema#string

J N Pande

http://www.w3.org/2001/XMLSchema#string

R K Tandon

http://www.w3.org/2001/XMLSchema#string

S Khilnani

http://www.w3.org/2001/XMLSchema#string

S P Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis and poverty

Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis

Drug treatment of tuberculosis--1992.

Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Toxic hepatitis with isoniazid and rifampin. A meta-analysis.

Malnutrition and drugs: clinical implications.

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.

Hepatitis cases in isoniazid treated groups and in a control group.

Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.

P304

132-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.51.2.132

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

1996-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14489994

http://www.w3.org/2001/XMLSchema#string

P698

8711642

http://www.w3.org/2001/XMLSchema#string

P921

P932

473016

http://www.w3.org/2001/XMLSchema#string